LX1032: Phase Ib start

This month, Lexicon will begin a double-blind, multiple-ascending dose, U.S. Phase Ib ( LX1606.102) trial of oral LX1032 in about 40 healthy volunteers. The company licensed LX1032 to Symphony last ye...